With a fresh phase 3 win for Kerendia, Bayer is one step closer to pushing the ascendant drug into a much broader population ...

Add Yahoo as a preferred source to see more of our stories on Google. The Bayer Pharma AG logo is seen on April 03, 2025 in Berlin, Germany. (Maja Hitij via Getty Images) This story was originally ...

Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s Eylea in a phase 3 study, teeing up filings for ...

Add Yahoo as a preferred source to see more of our stories on Google. Bayer's drug candidate to ease menopausal hot flashes was deemed safe and effective for long-term use in study results released ...

Bayer BAYRY announced that finerenone achieved the primary endpoint in the late-stage FIND-CKD study, marking a key milestone ...

Bayer (XTRA:BAYN) reported that its Phase III FIND-CKD trial for Kerendia met its primary endpoint. The study showed a ...

July 9 (Reuters) - The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased by an experimental non-hormonal drug being developed by ...

Bayer AG said an experimental stroke-prevention drug showed positive results in a late-stage study, a boost for the German company as it seeks to counter sales declines from aging blockbuster ...

Whippany-based Bayer is suing New Brunswick-headquartered Johnson & Johnson over claims the rival pharmaceutical company falsely advertised a competing prostate cancer drug. In a complaint filed Feb.

Bayer AG’s experimental drug cut the risk of secondary strokes without increasing serious bleeding in a late-stage trial, bolstering its prospects of driving growth for the German company as it faces ...